Horizon Pharma plc (HZNP) Stock | Spectacular Q3 Financial Results


Horizon Pharma plc (NASDAQ: HZNP)


Horizon Pharma plc (HZNP), a specialty pharmaceutical company on Friday announced positive third quarter 2015 financial results, and increased full year 2015 guidance. Net sales were $226.5 million an increase of 202% compared to third quarter 2014. Full year net sales guidance was increased to $750- $760 million up from $660 – $680 million. Full year EBITDA guidance was increased to $350-$360 million up from $265-$280 million.  


Horizon Pharma plc CEO Comments

“Our business fundamentals have never been better, we significantly exceeded expectations on net sales, adjusted EBITDA and adjusted diluted earnings per share and our cash flow generation continues to be very strong,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “As a result, we are significantly raising our full-year 2015 net sales and adjusted EBITDA guidance. Additionally, our Phase 3 trial for ACTIMMUNE in Friedreich’s ataxia is more than 30 percent enrolled, on track to complete enrollment in the second quarter of 2016 and we continue to expect results by the end of 2016.”  Market Wired


HZNP Technical Analysis


HZNP gapped up in price Friday to $20.00, up from the prior day’s close of $17.26, which is a 14% increase on the favorable news. Taking a look at the daily chart, we can see the last time HZNP traded above this price level was on October 5th, when it closed at $20.21. Taking a further look back on the chart we can see HZNP has been in an overall decline dating back to July 20th when the stock was trading at it 52 week high of $39.49. More recently, HZNP is bouncing off of lows of $12.86 reached on October 22nd. I would be looking to see if the stock can make a run past $21 which was the high of the last spike up on October 2nd. HZNP has a high float of 130.8 million shares and was trading 1.5 times the normal daily trading volume. HZNP did reach pre market highs of $20.90, but gave back $0.90 at the open, or equivalent to 4%. For trading purposes, my entry point would have been $20.10 looking for a run through $20.50. My stop loss would have been $19.90, fearing anything below that and the stock would start to fill in the gap up.


Company Profile

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pain of OA of the knee; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS). It also provides RAYOS/LODOTRA, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. The company has a collaboration agreement with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.  Yahoo Finance